AGEMICA
AGEMICA develops preventative vaccines and therapies intended to delay aging and prevent age-related diseases, increasing healthy human lifespan. The company uses artificial intelligence and machine learning to integrate large biological datasets — including all cancer types, millions of drug and biologic signatures, and human, viral, and bacterial protein data — to predict effective drug combinations and design disease-preventing vaccines. AGEMICA operates as an AI-driven biotechnology company that collaborates with pharmaceutical partners via licensing and revenue-sharing and can commercialize its own innovations. The team reports in silico and in vitro results showing selective eradication of cancer cells across multiple cancer types without harming healthy cells. The approach targets broad chronic-disease indications with the goal of scaling to many age-related conditions and expanding market reach.
AGEMICA
AGEMICA develops preventative vaccines and therapies intended to delay aging and prevent age-related diseases, increasing healthy human lifespan. The company uses artificial intelligence and machine learning to integrate large biological datasets — including all cancer types, millions of drug and biologic signatures, and human, viral, and bacterial protein data — to predict effective drug combinations and design disease-preventing vaccines. AGEMICA operates as an AI-driven biotechnology company that collaborates with pharmaceutical partners via licensing and revenue-sharing and can commercialize its own innovations. The team reports in silico and in vitro results showing selective eradication of cancer cells across multiple cancer types without harming healthy cells. The approach targets broad chronic-disease indications with the goal of scaling to many age-related conditions and expanding market reach.